Arca
Skip to content

Multifocal motor neuropathy (mmn)

Drug research and approvals for multifocal motor neuropathy (mmn): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 1 studies of multifocal motor neuropathy (mmn) are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 1
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 1 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jun 18, 2026An open-label, single-arm, phase 1b study to evaluate the effect of empasiprubart on nerve morphology by ultrasound in adults with multifocal motor neuropathyEMPASIPRUBART (ARGX-117)argenx US, Inc.Pending
May 16, 2025A phase 3, randomized, double-blinded, double-dummy study evaluating the efficacy and safety of empasiprubart versus intravenous immunoglobulin in adults with…EMPASIPRUBART (ARGX-117) / OCTAGAM / SODIUM CHLORIDEargenx US, Inc.Ongoing
Apr 23, 2025A phase 2, randomized, double-blinded, placebo-controlled, study to evaluate safety, tolerability, pharmacometrics, and efficacy of dnth103 in adults with…DNTH103DIANTHUS THERAPEUTICS, INCOngoing
Nov 3, 2022A long-term extension of the argx-117-2002 trial to evaluate the long-term safety and tolerability, efficacy, pharmacodynamics, pharmacokinetics, and…ARGX-117argenx US, Inc.Closed
Jan 12, 2022A phase 2, randomized, double-blinded, placebo-controlled, parallel-group, multicenter trial to evaluate the safety and tolerability, efficacy,…ARGX-117argenx US, Inc.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first
Jun 22, 2012Gammagard LiquidMaintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).Takeda Pharmaceuticals U.S.A., Inc.Approved
Jun 5, 2024empasiprubarttreatment of multifocal motor neuropathyargenx BVDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.